REVIEW PAPER
Mechanisms of carcinogenesis in colorectal cancer
1
Department of Physiology, Institute of Medical Science, Faculty of Medicine and Health Science, Jan Kochanowski University, Kielce, Poland
Submission date: 2017-11-13
Acceptance date: 2017-12-11
Publication date: 2017-12-31
Medical Studies 2017;33(4):308-315
KEYWORDS
TOPICS
ABSTRACT
Colorectal cancer should be considered as a heterogeneous disease that leads to many different genetic changes, resulting in the existence of molecular subtypes that differ in response to the same treatment and have different prognosis. For this reason, research into new, sensitive, and specific molecular prognostic factors has been intensified. It is now clear that there are many pathways leading to tumour formation in this organ because only about 10% of intestinal tumours have mutations in three “classic” Fearon-Vogelstein genes: APC, KRAS, and P53. The study of the relationship between molecular changes and clinical and pathological features reflects the evolution of the disease. Effective care for the sick depends on appropriate pathological evaluation and the ability to perform effective research on disease mechanisms.
REFERENCES (28)
1.
Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990; 61: 759-767.
2.
Vogelstein B, Fearon ER, Hamilton SR. Genetic alterations during colorectal – tumor development. N Engl J Med 1988; 319: 525-522.
3.
Vogelstein B, Fearon ER, Kern SE, Hamilton SR, Preisinger AC, Nakamura Y, White R. Allelotype of colorectal carcinomas. Science 1989; 244: 207-211.
4.
Żelazowski MJ, Bednarek AK. Molekularne modele nowotworzenia w raku jelita i odbytnicy. Współcz Onkol 2010; 14: 181-188.
5.
Bartczak M, Sałagacka A, Mirowski M, Balcerczak E. Status genu K-RAS jako czynnik prognostyczny i predykcyjny w raku jelita grubego. J Oncol 2010; 60: 147-156.
6.
Douillard JY. Panitumumab – FOLFOX4 treatment and RAS mutations in colorectal cancer. N Eng J Med 2013; 369: 1023-1034.
7.
Losi L, Ponz DL, Jiricny J, Di Gregorio C, Benatti P, Percesepe A, Fante R, Roncucci L, Pedroni M, Benhattar J. K-ras and p53 mutations in hereditary non-polyposis colorectal cancers. Int J Cancer 1997; 74: 94-96.
8.
Kern HB, Niemeyer BF, Parrish JK, Kerr CA, Yaghi NK, Prescott JD, Gutierrez-Hartmann A, Jedlicka P. Control of microRNA-21 expression in colorectal cancer cells by oncogenic epidermal growth factor/Ras signaling and Ets transcription factors. DNA Cell Biol 2012; 31: 1403-1411.
9.
De Stefano A, Carlomagno C. Beyond KRAS: predictive factors of the efficacy of anti-EGFR monoclonal antibodies in the treatment of metastatic colorectal cancer. World J Gastroenterol 2014; 20: 9732-9743.
10.
Bando H, Yoshino T, Shinozaki E, Nishina T, Yamazaki K, Yamaguchi K, Yuki S, Kajiura S, Fujii S, Yamanaka T, Tsuchihara K, Ohtsu A. Simultaneous identification of 36 mutations in KRAS codons 61 and 146, BRAF, NRAS, and PIK3CA in a single reaction by multiplex assay kit. BMC Cancer 2013; 13: 405.
11.
Ines C, Donia O, Rahma B, Ben Ammar A, Sameh A, Khalfallah T, Abdelmajid BH, Sabeh M, Saadia B. Implication of K-ras and p53 in colorectal cancer carcinogenesis in Tunisian population cohort. Tumour Biol 2014; 35: 7163-7175.
12.
Knickelbein K, Zhang L. Mutant KRAS as a critical determinant of the therapeutic response of colorectal cancer. Genes Dis 2015; 2: 4-12.
13.
Xu XM, Qian JC, Cai Z, Tang T, Wang P, Zhang KH, Deng ZL, Cai JP. DNA alterations of microsatellite DNA, p53, APC and K-ras in Chinese colorectal cancer patients. Eur J Clin Invest 2012; 42: 751-759.
14.
Alpan RS, Pardee AB. p21WAF1/CIP1/SDI1 is elevated through a p53-independent pathway by mimosine. Cell Growth Differ 1996; 7: 893-901.
15.
Hill R, Rabb M, Madureira PA, Clements D, Gujar SA, Waisman DM, Giacomantonio CA, Lee PW. Gemcitabine-mediated tumour regression and p53-dependent gene expression: implications for colon and pancreatic cancer therapy. Cell Death Dis 2013; 4: e791.
16.
Huerta S, Gao X, Dineen S, Kapur P, Saha D, Meyer J. Role of p53, Bax, p21, and DNA-PKcs in radiation sensitivity of HCT-116 cells and xenografts. Surgery 2013; 154: 143-151.
17.
Lam AK, Ong K, Ho YH. Colorectal mucinous adenocarcinoma: the clinicopathologic features and significance of p16 and p53 expression. Dis Colon Rectum 2006; 49: 1275-1283.
19.
Krakowczyk Ł, Strzelczyk JK. Epigenetyczna modyfikacja ekspresji genów w rozwoju raka jelita grubego. Współcz Onkol 2007; 11: 289-294.
20.
Knudson AG Jr. Hereditary cancer, oncogenes, and antioncogenes. Cancer Res 1985; 45: 1437-1443.
21.
Iino H, Simms L, Young J, Arnold J, Winship IM, Webb Sl, Furlong KL, Leggett B, Jass JR. DNA microsatellite instability and mismatch repair protein loss in adenomas presenting in hereditary non-polyposis colorectal cancer. Gut 2000; 47: 37-42.
22.
Samowitz WS, Slattery ML, Sweeney C, Herrick J, Wolff RK, Albertsen H. APC mutations and other genetic and epigenetic changes in colon cancer. Mol Cancer Res 2007; 5: 165-170.
23.
Hawkins N, Norrie M, Cheong K, Mokany E, Ku SL, Meagher A, O’Conor T, Ward R. CpG island methylation in sporadic colorectal cancers and its relationship to microsatellite instability. Gastroenterology 2002; 122: 1376-1387.
24.
Jass JR, Iino H, Ruszkiewicz A, Painter D, Solomon MJ, Koorey DJ, Cohn D, Furlong KL, Walsh MD, Palazzo J, Edmonston TB, Fishel R, Young J, Leggett BA. Neoplastic progression occurs through mutator pathways in hyperplastic polyposis of the colorectum. Gut 2000; 47: 43-49.
25.
Jass JR. Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. Histopathology 2007; 50: 113-130.
26.
Ayroldi E, Petrillo MG, Bastianelli A, Marchetti MC, Ronchetti S, Nocentini G, Ricciotti L, Cannarile L, Riccardi C. L-GILZ binds p53 and MDM2 and suppresses tumor growth through p53 activation in human cancercells. Cell Death Differ 2015; 22: 118-130.
27.
Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991; 253: 49-53.
28.
Kuremsky JG, Tepper JE, McLeod H. Biomarkers for response to neoadjuvant chemoradiation for rectal cancer. Int J Radiation Oncology Biol Phys 2009; 74: 673-688.
Share
RELATED ARTICLE
| eISSN: | 2300-6722 |
| ISSN: | 1899-1874 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
